Terms: = Lung cancer AND MAF, MGC71685, 4094, ENSG00000178573 AND Treatment
24 results:
1. mafF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinoma.
Liang J; Bi G; Huang Y; Zhao G; Sui Q; Zhang H; Bian Y; Yin J; Wang Q; Chen Z; Zhan C
Drug Resist Updat; 2024 Mar; 73():101057. PubMed ID: 38266355
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of
Lastraioli E; Bettiol A; Iorio J; Limatola E; Checcacci D; Parisi E; Bianchi C; Arcangeli A; Iannopollo M; Di Costanzo F; Di Lieto M
Cells; 2023 May; 12(11):. PubMed ID: 37296579
[TBL] [Abstract] [Full Text] [Related]
3. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.
Gerratana L; Movarek M; Wehbe F; Katam N; Mahalingam D; Donahue J; Shah A; Chae YK; Mulcahy M; Tsarwhas D; Villaflor V; Kalyan A; Hussein M; Patel J; Chandra S; Platanias LC; Gradishar W; Cristofanilli M; Behdad A
JCO Precis Oncol; 2022 Jun; 6():e2100289. PubMed ID: 35772051
[TBL] [Abstract] [Full Text] [Related]
4. Acoustic Array Biochip Combined with Allele-Specific PCR for Multiple cancer Mutation Analysis in Tissue and Liquid Biopsy.
Naoumi N; Michaelidou K; Papadakis G; Simaiaki AE; Fernández R; Calero M; Arnau A; Tsortos A; Agelaki S; Gizeli E
ACS Sens; 2022 Feb; 7(2):495-503. PubMed ID: 35073481
[TBL] [Abstract] [Full Text] [Related]
5. Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell lung cancer and Melanoma: A Systematic Review.
Rodríguez Plá M; Dualde Beltrán D; Ferrer Albiach E
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769050
[No Abstract] [Full Text] [Related]
6. Discovery and characterization of novel peptide inhibitors of the NRF2/mafG/DNA ternary complex for the treatment of cancer.
Simov V; Altman MD; Bianchi E; DelRizzo S; DiNunzio EN; Feng G; Goldenblatt P; Ingenito R; Johnson SA; Mansueto MS; Mayhood T; Mortison JD; Serebrov V; Sondey C; Sriraman V; Tucker TJ; Walji A; Wan H; Yue Y; Stoeck A; DiMauro EF
Eur J Med Chem; 2021 Nov; 224():113686. PubMed ID: 34303079
[TBL] [Abstract] [Full Text] [Related]
7. lungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.
Garrido P; Paz-Ares L; Majem M; Morán T; Trigo JM; Bosch-Barrera J; Garcίa-Campelo R; González-Larriba JL; Sánchez-Torres JM; Isla D; Viñolas N; Camps C; Insa A; Juan Ó; Massuti B; Paredes A; Artal Á; López-Brea M; Palacios J; Felip E
Cancer Med; 2021 Sep; 10(17):5878-5888. PubMed ID: 34296539
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Chara L; Hernández B; Padilla A; Coves J; Blanco R; Balsalobre J; Mielgo X; Bueno C; Jantus-Lewintre E; Molina-Vila MÁ; Romero A
Eur J Cancer; 2021 May; 149():61-72. PubMed ID: 33831609
[TBL] [Abstract] [Full Text] [Related]
9. Can Quantitative Measures of T790M Allelic Fraction Predict Survival Outcomes in Patients Receiving Osimertinib? Observations From an Early Access Programme.
Chan OSH; Lee VHF; Nyaw SF; Kam MTY; Lee KWC; Lam KC
Clin Oncol (R Coll Radiol); 2021 Jul; 33(7):e305-e314. PubMed ID: 33589348
[TBL] [Abstract] [Full Text] [Related]
10. Detection of
Michaelidou K; Koutoulaki C; Mavridis K; Vorrias E; Papadaki MA; Koutsopoulos AV; Mavroudis D; Agelaki S
Cells; 2020 Nov; 9(11):. PubMed ID: 33233668
[No Abstract] [Full Text] [Related]
11. High maf of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract] [Full Text] [Related]
12. c-maf: a bad influence in the education of macrophages.
Conejo-Garcia JR; Rodriguez PC
J Clin Invest; 2020 Apr; 130(4):1629-1631. PubMed ID: 32175921
[TBL] [Abstract] [Full Text] [Related]
13. Transcription factor c-maf is a checkpoint that programs macrophages in lung cancer.
Liu M; Tong Z; Ding C; Luo F; Wu S; Wu C; Albeituni S; He L; Hu X; Tieri D; Rouchka EC; Hamada M; Takahashi S; Gibb AA; Kloecker G; Zhang HG; Bousamra M; Hill BG; Zhang X; Yan J
J Clin Invest; 2020 Apr; 130(4):2081-2096. PubMed ID: 31945018
[TBL] [Abstract] [Full Text] [Related]
14. Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.
Tang Y; Che N; Yu Y; Gao Y; Shi H; Feng Q; Wei B; Ma L; Gao M; Ma J; Lin D
J Cancer Res Clin Oncol; 2020 Feb; 146(2):407-416. PubMed ID: 31696302
[TBL] [Abstract] [Full Text] [Related]
15. LncRNA mafG-AS1 facilitates the migration and invasion of NSCLC cell via sponging miR-339-5p from MMP15.
Jia YC; Wang JY; Liu YY; Li B; Guo H; Zang AM
Cell Biol Int; 2019 Apr; 43(4):384-393. PubMed ID: 30599080
[TBL] [Abstract] [Full Text] [Related]
16. Radiologic types of Mycobacterium xenopi pulmonary disease: different patients with similar short-term outcomes.
Hirama T; Brode SK; Marras TK
Eur J Clin Microbiol Infect Dis; 2019 Feb; 38(2):373-381. PubMed ID: 30552538
[TBL] [Abstract] [Full Text] [Related]
17. Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset.
Ullah K; Zubia E; Narayan M; Yang J; Xu G
FEBS J; 2019 Jun; 286(11):2018-2034. PubMed ID: 30468556
[TBL] [Abstract] [Full Text] [Related]
18. The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.
Del Re M; Bordi P; Rofi E; Restante G; Valleggi S; Minari R; Crucitta S; Arrigoni E; Chella A; Morganti R; Tiseo M; Petrini I; Danesi R
Br J Cancer; 2018 Nov; 119(10):1252-1258. PubMed ID: 30397287
[TBL] [Abstract] [Full Text] [Related]
19. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
[TBL] [Abstract] [Full Text] [Related]
20. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors.
Singh A; Venkannagari S; Oh KH; Zhang YQ; Rohde JM; Liu L; Nimmagadda S; Sudini K; Brimacombe KR; Gajghate S; Ma J; Wang A; Xu X; Shahane SA; Xia M; Woo J; Mensah GA; Wang Z; Ferrer M; Gabrielson E; Li Z; Rastinejad F; Shen M; Boxer MB; Biswal S
ACS Chem Biol; 2016 Nov; 11(11):3214-3225. PubMed ID: 27552339
[TBL] [Abstract] [Full Text] [Related]
[Next]
